Recrutamento encerrado
FASE
Número Europeu 2021-003461-35
20210096 FORTITUDE-101
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
Detalhes
Destaques